Survodutide: The GLP-1/Glucagon Dual Agonist That Could Reshape Obesity and MASH Treatment

Survodutide targets both the GLP-1 and glucagon receptors — and its Phase 3 SYNCHRONIZE readout, expected any day in 2026, could reframe how we think about obesity treatment and metabolic liver disease.

Read more

Support ✨
📞 Call
Hi there! Want to chat via voice? Click the Call button! 😊
🤖
Listening...
Speak naturally with the agent
📞